INOVIO Pharmaceuticals to Outline Strategy at December Investor Conferences
INOVIO Pharmaceuticals (NASDAQ:INO), a biotechnology company focused on DNA medicines, is scheduled to participate in two investor conferences in December to discuss its strategic initiatives.
The company will first attend the Piper Sandler 37th Annual Healthcare Conference in New York on December 2. The event will feature a fireside chat with INOVIO's management, which will be available via a live webcast. Piper Sandler currently maintains an Overweight rating on the company's stock.
INOVIO will also attend the Oppenheimer Movers in Rare Disease Summit on December 11. At this event, the company will participate in a panel discussion focusing on key near-term catalysts.
The company's stock was recently priced at $1.79, a 5.29% decrease from the previous price of $1.95. The stock has seen a 52-week high of $4.61 and a low of $1.30. The trading range for the day was between $1.78 and $1.90.
INOVIO's market capitalization stands at approximately $95.93 million, with a trading volume of 1,073,702 shares on the NASDAQ exchange. Management will hold one-on-one meetings with investors during both conferences.
Inovio Pharmaceuticals, Inc. (INO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.